CTLA4 and rheumatoid arthritis: Also stratifying RA patients according to the drug treatment, no significant differences were found: TNF-α inhibitors (T1 median: 89.6 pg/ml, IQR: 42.5–254.6 vs. T6 median: 83 pg/ml, IQR: 28–268, p > 0.999), IL-6 inhibitors (T1 median: 41.3 pg/ml, IQR: 19.5–80.5 vs. T6 median: 170 pg/ml, IQR: 30.6–258, p = 0.297), CTLA-4-Ig (T1 median: 7.42 pg/ml, IQR: 3.03–35.3 vs. T6 median: 7.10 pg/ml, IQR: 2.4–27.6, p = 0.160) and DMARDs±CCSs (T1 median: 130 pg/ml, IQR: 17.2–364 vs. T6 median: 91.0 pg/ml, IQR: 45.3–268, p = 0.578) (Figure 9C).